泊沙康唑及其他抗真菌剂对通过内转录间隔区测序鉴定的毛霉目菌株的活性。
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
作者信息
Alastruey-Izquierdo Ana, Castelli Maria Victoria, Cuesta Isabel, Monzon Araceli, Cuenca-Estrella Manuel, Rodriguez-Tudela Juan Luis
机构信息
Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Spain.
出版信息
Antimicrob Agents Chemother. 2009 Apr;53(4):1686-9. doi: 10.1128/AAC.01467-08. Epub 2009 Jan 26.
Abstract
The antifungal susceptibility profiles of 77 clinical strains of Mucorales species, identified by internal transcribed spacer sequencing, were analyzed. MICs obtained at 24 and 48 h were compared. Amphotericin B was the most active agent against all isolates, except for Cunninghamella and Apophysomyces isolates. Posaconazole also showed good activity for all species but Cunninghamella bertholletiae. Voriconazole had no activity against any of the fungi tested. Terbinafine showed good activity, except for Rhizopus oryzae, Mucor circinelloides, and Rhizomucor variabilis isolates.
摘要
分析了通过内转录间隔区测序鉴定的77株毛霉目菌种临床菌株的抗真菌药敏谱。比较了在24小时和48小时获得的最低抑菌浓度（MIC）。除了小克银汉霉和犁头霉分离株外，两性霉素B对所有分离株都是最有效的药物。泊沙康唑对除贝氏小克银汉霉外的所有菌种也显示出良好活性。伏立康唑对所测试的任何真菌均无活性。特比萘芬显示出良好活性，但对米根霉、卷枝毛霉和多变根毛霉分离株除外。
相似文献
1
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
Antimicrob Agents Chemother. 2009 Apr;53(4):1686-9. doi: 10.1128/AAC.01467-08. Epub 2009 Jan 26.
2
Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.
J Clin Microbiol. 2012 Jan;50(1):66-75. doi: 10.1128/JCM.06133-11. Epub 2011 Nov 9.
3
The environmental source of emerging Apophysomyces variabilis infection in India.
Med Mycol. 2016 Aug 1;54(6):567-75. doi: 10.1093/mmy/myw014. Epub 2016 Apr 26.
4
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.
Antimicrob Agents Chemother. 2015 Dec;59(12):7735-42. doi: 10.1128/AAC.01919-15. Epub 2015 Oct 5.
5
A Revised Species Concept for Opportunistic Species Reveals Species-Specific Antifungal Susceptibility Profiles.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00653-19. Print 2019 Aug.
6
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.
Antimicrob Agents Chemother. 2015 Mar;59(3):1745-50. doi: 10.1128/AAC.04435-14. Epub 2015 Jan 12.
7
Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure.
Med Mycol. 2023 Apr 29;61(5). doi: 10.1093/mmy/myad045.
8
Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00266-19. Print 2019 May.
9
In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
J Antimicrob Chemother. 2012 Aug;67(8):1937-40. doi: 10.1093/jac/dks137. Epub 2012 Apr 25.
10
Activity of deferasirox in Mucorales: influences of species and exogenous iron.
Antimicrob Agents Chemother. 2011 Jan;55(1):411-3. doi: 10.1128/AAC.00792-10. Epub 2010 Oct 18.
引用本文的文献
1
SIADH secondary to rhino-orbito-cerebral mucormycosis: A case report.
Clin Case Rep. 2024 Nov 12;12(11):e9491. doi: 10.1002/ccr3.9491. eCollection 2024 Nov.
2
Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.
Front Microbiol. 2024 Feb 12;15:1354757. doi: 10.3389/fmicb.2024.1354757. eCollection 2024.
3
In vitro combination with doxycycline plus antifungals against clinical Mucorales pathogens.
Braz J Microbiol. 2023 Dec;54(4):2597-2602. doi: 10.1007/s42770-023-01167-z. Epub 2023 Nov 7.
4
COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.
Mycopathologia. 2023 Oct;188(5):783-792. doi: 10.1007/s11046-023-00785-3. Epub 2023 Sep 6.
5
Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.
J Fungi (Basel). 2023 Jun 12;9(6):659. doi: 10.3390/jof9060659.
6
A peek behind the curtain in the diagnosis and management of COVID‑19‑Associated Mucormycosis (CAM).
J Egypt Public Health Assoc. 2023 Mar 2;98(1):4. doi: 10.1186/s42506-022-00125-1.
7
Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.
Environ Sci Pollut Res Int. 2023 Jan;30(4):9164-9183. doi: 10.1007/s11356-022-24032-2. Epub 2022 Dec 1.
8
A 40-Year-Old Woman With COVID-19 and Bilateral Vision Loss.
Neurohospitalist. 2022 Oct;12(4):664-668. doi: 10.1177/19418744221114209. Epub 2022 Jul 13.
9
COVID-19 Associated Mucormycosis: A Systematic Review from Diagnostic Challenges to Management.
Diseases. 2021 Sep 22;9(4):65. doi: 10.3390/diseases9040065.
10
First reported case of Gilbertella persicaria in human stool: outcome of a community study from Segamat, Johor, Malaysia.
Braz J Microbiol. 2020 Dec;51(4):2067-2075. doi: 10.1007/s42770-020-00323-z. Epub 2020 Jun 23.
本文引用的文献
1
EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.
Clin Microbiol Infect. 2008 Oct;14(10):982-4. doi: 10.1111/j.1469-0691.2008.02086.x.
2
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
Antimicrob Agents Chemother. 2008 Jul;52(7):2636-8. doi: 10.1128/AAC.00492-08. Epub 2008 May 5.
3
Treatment of zygomycosis: current and new options.
J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i35-40. doi: 10.1093/jac/dkm429.
4
Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: can MIC values be obtained at 24 hours?
Antimicrob Agents Chemother. 2007 Dec;51(12):4502-4. doi: 10.1128/AAC.00933-07. Epub 2007 Oct 15.
5
Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.
Transpl Infect Dis. 2007 Jun;9(2):89-96. doi: 10.1111/j.1399-3062.2007.00208.x.
6
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
Antimicrob Agents Chemother. 2007 Jul;51(7):2587-90. doi: 10.1128/AAC.00452-07. Epub 2007 Apr 23.
7
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
Bone Marrow Transplant. 2007 Apr;39(7):425-9. doi: 10.1038/sj.bmt.1705614. Epub 2007 Feb 19.
8
Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates.
Antimicrob Agents Chemother. 2007 Feb;51(2):748-51. doi: 10.1128/AAC.01177-06. Epub 2006 Nov 13.
9
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Antimicrob Agents Chemother. 2006 Mar;50(3):917-21. doi: 10.1128/AAC.50.3.917-921.2006.
10
Epidemiology and outcome of zygomycosis: a review of 929 reported cases.
Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29.
Zotero 插件